Elias Jabbour, Gerhard Zugmaier, Vaibhav Agrawal, Pilar Martínez-Sánchez, José J Rifón Roca, Ryan D Cassaday, Boris Böll, Anita Rijneveld, Maher Abdul-Hay, Françoise Huguet, Thomas Cluzeau, Mar Tormo Díaz, Vladan Vucinic, José González-Campos, Alessandro Rambaldi, Stefan Schwartz, Céline Berthon, Jesús María Hernández-Rivas, Paul R Gordon, Monika Brüggemann, Ali Hamidi, Yuqi Chen, Hansen L Wong, Bharat Panwar, Yuliya Katlinskaya, Ana Markovic, Hagop Kantarjian
Blinatumomab is a BiTE® (bispecific T-cell engager) molecule that redirects CD3+ T-cells to engage and lyse CD19+ target cells. Here we demonstrate that subcutaneous (SC) blinatumomab can provide high efficacy and greater convenience of administration. In the expansion phase of a multi-institutional phase 1b trial (ClinicalTrials.gov, NCT04521231), heavily pretreated adults with relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL) received SC blinatumomab at two doses: (1) 250 μg once daily (QD) for week 1 and 500 μg three times weekly (TIW) thereafter (250 μg/500 μg) or (2) 500 μg QD for week 1 and 1000 μg TIW thereafter (500 μg/1000 μg)...
February 5, 2024: American Journal of Hematology